Barclays PLC Increases Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Barclays PLC lifted its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 24.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,674 shares of the company’s stock after purchasing an additional 1,109 shares during the period. Barclays PLC’s holdings in ClearPoint Neuro were worth $64,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at approximately $175,000. Squarepoint Ops LLC acquired a new position in ClearPoint Neuro during the second quarter worth $549,000. Renaissance Technologies LLC boosted its position in ClearPoint Neuro by 562.6% during the second quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock worth $915,000 after purchasing an additional 144,088 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in ClearPoint Neuro in the second quarter valued at $419,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter valued at $156,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Stock Down 2.4 %

NASDAQ:CLPT opened at $15.07 on Friday. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $17.47. The stock has a fifty day simple moving average of $13.72 and a 200-day simple moving average of $11.28. The company has a market capitalization of $415.71 million, a PE ratio of -21.84 and a beta of 1.01.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.